Omada Health, Inc.

Listed Company

OMDACIK 0001611115NasdaqNon-AcceleratedEmerging GrowthServices-Health ServicesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$260.21M

Net Income

$-12.78M

Total Assets

$305.41M

Equity

$229.68M

Shares Out

58.93M

Op. Cash Flow

$18.25M

Business

Omada Health, Inc. is a publicly listed company in Health Services, incorporated in Delaware. Common stock trades on Nasdaq under the ticker OMDA.

Auto-generated from company profile

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Total revenue	260	170	123
Total cost of revenue	89	67	53
Gross profit	171	103	70
Research and development	41	36	34
Sales and marketing	90	68	66
General and administrative	52	43	36
Total operating expenses	183	147	136
Operating loss	−12	−44	−66
Interest expense	−3	−5	−5
Interest income	5	805,000	6
Loss on debt extinguishment	−2	0	−2
Change in fair value of warrants	−1	218,000	−1
Total other expense, net	−806,000	−3	−2
Loss before provision for income taxes	−13	−47	−68
Provision for income taxes	0	0	0
Net loss and comprehensive loss	−13	−47	−68
Net loss and comprehensive loss	−13	−47	−68
Basic (in dollars per share)	−0.35	−6.11	−9.52
Diluted (in dollars per share)	−0.35	−6.11	−9.52
Basic (in shares)	37	8	7
Diluted (in shares)	37	8	7

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	222	76	—	—
Accounts receivable, net	35	23	—	—
Inventory	4	3	—	—
Deferred commissions, current	4	3	—	—
Contract assets	638,000	502,000	—	—
Prepaid expenses and other current assets	8	7	—	—
Total current assets	273	113	—	—
Property and equipment, net	8	6	—	—
Operating lease right-of-use asset	0	447,000	—	—
Deferred commissions, non-current	9	9	—	—
Intangible assets, net	2	4	—	—
Goodwill	13	13	—	—
Other assets	165,000	5	—	—
Total assets	305	151	—	—
Accounts payable	10	4	—	—
Accrued expenses and other current liabilities	40	30	—	—
Operating lease liability, current	0	415,000	—	—
Deferred revenue	25	20	—	—
Total current liabilities	76	54	—	—
Long term debt	0	30	—	—
Warrant liabilities, non-current	0	2	—	—
Other liabilities, non-current	0	285,000	—	—
Total liabilities	76	86	—	—
Commitments and contingencies (Note 7)	—	—	—	—
Redeemable convertible preferred stock, $0.001 par value per share; no shares and 120,689 shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares and 118,219 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $0 and $455,588 as of December 31, 2025 and December 31, 2024, net of issuance costs	0	449	449	449
Common stock, $0.001 par value per share; 750,000 and 181,500 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 58,429 and 8,157 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	58,000	8,000	—	—
Additional paid-in capital	686	60	—	—
Accumulated deficit	−457	−444	—	—
Total stockholders equity (deficit)	230	−384	−350	−293
Total liabilities, redeemable convertible preferred stock and stockholders equity (deficit)	305	151	—	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Depreciation and amortization	5	5	4
Share-based compensation	13	9	9
Loss on disposal of property and equipment	8,000	2,000	151,000
Amortization of debt issuance costs	285,000	389,000	416,000
Non-cash operating lease expense	447,000	728,000	683,000
Provision for credit losses	1	2	452,000
Amortization of deferred commissions	3	3	2
Accounts receivable	−12	−9	−5
Inventory	−1	318,000	−74,000
Prepaid expenses and other current assets	−1	−2	−1
Deferred commissions	−4	−6	−4
Other non-current assets	251,000	409,000	213,000
Accounts payable	6	399,000	−286,000
Operating lease liabilities	−415,000	−783,000	−716,000
Accrued expenses and other current liabilities	11	5	8
Deferred revenue	6	5	1
Other non-current liabilities	0	180,000	105,000
Net cash provided by (used in) operating activities	18	−34	−50
Purchases of property and equipment	−1	−596,000	−416,000
Capitalized internal-use software costs	−5	−3	−3
Net cash used in investing activities	−6	−4	−3
Proceeds from issuance of Midcap term facility	0	0	31
Payment of Midcap term facility issuance costs	0	0	−2
Proceeds from exercise of stock options	9	3	2
Payment of deferred offering costs	−4	−5	−111,000
Payment of debt extinguishment costs	−1	0	−623,000
Proceeds from initial public offering, net of underwriting discounts and commissions	161	0	0
Net cash provided by (used in) financing activities	133	−1	179,000
Net increase (decrease) in cash and cash equivalents	146	−39	−52
Interest	2	4	4
Share-based compensation expense capitalized in internal-use software	184,000	97,000	76,000
Unpaid deferred offering costs included in accounts payable	0	131,000	23,000
Unpaid property and equipment included in accounts payable	16,000	65,000	26,000
Conversion of redeemable convertible preferred stock in connection with initial public offering	452	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro